2012-10-05 16:30:55 - Recently published research from Global Markets Direct, "Cachexia - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Cachexia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cachexia. Cachexia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468372_cachexia_pipeline_review_h2_2012.aspx


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for

the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Cachexia.
* A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Cachexia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Cachexia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cachexia Overview
Therapeutics Development
An Overview of Pipeline Products for Cachexia
Cachexia Therapeutics under Development by Companies
Cachexia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Cachexia Therapeutics - Products under Development by Companies
Cachexia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cachexia Therapeutics Development
Eli Lilly and Company
Inovio Biomedical Corporation
BioLineRx, Ltd.
Novartis AG
Aphios Corporation
AEterna Zentaris Inc.
Calzada Limited
Palatin Technologies, Inc.
Cytokinetics, Inc
Galapagos NV
Asubio Pharmaceuticals, Inc.
Helsinn Healthcare S.A.
Alder Biopharmaceuticals Inc.
Tranzyme Pharma, Inc.
KangLaiTe USA
Fate Therapeutics, Inc.
Elixir Pharmaceuticals, Inc.
Vicus Therapeutics, LLC
Amunix, Inc.
OHR Pharmaceutical Inc.
Acacia Pharma Ltd.
Rhythm Pharmaceuticals
Cachexia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SUN-11031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEZS-130 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RM-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-5040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ulimorelin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Delta 9-THC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Delta 9-THCA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clazakizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EX-1314 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-3200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AOD-9604 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kanglaite - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-100192 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ghrelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APD209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-6020 - Drug Profile
Product Description

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468372&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.